In short, Dihexa is not a typical cognitive enhancer its an experimental peptide aimed at rewiring the brain itself, making it one of the most talked-about but also most controversial research compounds in the nootropic space
ADDITIONAL COMMERCIALIZATION MODELS: 2006-2012 At the same time that the Services were starting to experiment with different commercialization mechanisms through CPP, other efforts to enhance commercialization relevant for SBIR were also gaining some traction within DoD
Separately, in 2026 the FDA and HHS signaled moving several peptides, including injectable GHK-Cu, BPC-157, and TB-500, toward a compounding-eligible category
Key finding: Genetic NNMT knockdown increased energy expenditure, reduced adipose tissue by 30% , and elevated NAD+ and SAM levels validating NNMT as a high-value target
The goal is not rapid transformation but gradual improvements that support long-term health and quality of life
Its hard to project how long it will take to have something we can test in patients, but my aim is to have something within a matter of weeks
